ISSWSH ISSUES IMPORTANT UPDATES FOR HSDD THERAPIES

ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.

News Release

Save the Date

ISSWSH Annual Meeting 2022

March 3-6, 2022   38 days left
Renaissance Dallas Hotel - Dallas, TX
Visit the Meeting Website

ISSWSH Fall Course 2022

November 17-20, 2022   294 days left
DoubleTree Resort - Paradise Valley - Scottsdale, AZ
Visit the Course Website

ISSWSH Annual Meeting 2023

March 2-5, 2023   399 days left
Marriott St. Louis Grand - St. Louis, MO
Visit the Meeting Website

Latest Tweets

Body image in menopause and sexual function- it's associated. Should postmenopause health promotion address and inc… https://t.co/UddSaT4xmn ISSWSH
A new anatomical study describes the attachments of the clitoris to the abdominal wall, with implications for surgi… https://t.co/XSWvFzGP4u ISSWSH
Today is World Lichen Sclerosus Day. #lichensclerosus is an inflammatory skin condition that primarily affects the… https://t.co/GhYc4qu0x5 ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram